Erythropoietin and analogs

Article written and reviewed by Dr Luca Moretti

The clinical introduction of recombinant human erythropoietin (rhEPO) and its analogs marked a turning point in transfusion medicine and clinical hematology, transforming the management of chronic anemia especially in kidney failure and systemic chronic disease. Erythropoietin is not merely a drug, but a model of physiologic targeted hormone replacement therapy based on knowledge of the processes that regulate red blood cell production in humans.

Erythropoietin treatment is a selective strategy that, in appropriate indications, reduces transfusion requirements and may improve some symptoms and domains of quality of life; benefits and risks vary according to the clinical context, and a general prognostic advantage has not been demonstrated.

Physiology of erythropoietin and regulation of erythropoiesis

Erythropoietin is a 165 amino acid glycoprotein, produced for more than 90% by peritubular interstitial cells of the adult kidney and, to a lesser extent, by the liver, which instead has a major role during fetal life. Its primary function is regulation of proliferation, differentiation and survival of erythroid progenitors, especially BFU E and CFU E, in the bone marrow. Activation of the EPO gene is tightly controlled by renal oxygen partial pressure through the hypoxia inducible factor system. In hypoxic conditions, including anemia, hypoperfusion and altitude, stabilization mainly of HIF 2 alpha increases erythropoietin synthesis and stimulates erythroid production to restore adequate tissue oxygenation.

At the molecular level, erythropoietin acts by binding to EpoR on erythroid progenitor cells. This interaction activates the JAK2 STAT5, PI3K AKT and MAPK pathways, promoting cell survival through inhibition of apoptosis, proliferation and precursor maturation. The final effect is an increase in circulating red blood cell mass.

This physiologic regulation is altered in numerous pathologic conditions. In chronic kidney disease, loss of renal parenchyma results in erythropoietin production that is inappropriately low for the degree of anemia, together with inflammation and iron restriction, producing the typical normocytic, normochromic anemia observed in these patients. In chronic inflammatory diseases, cytokines, especially IL 6 and TNF alpha, both reduce the sensitivity of erythroid progenitors to EPO, causing erythropoietin resistance, and increase hepcidin, which limits the bioavailability of iron required for erythropoiesis.

Historical overview and rationale for therapy

Isolation and cloning of the human EPO gene enabled production of recombinant forms, changing above all the management of anemia of chronic kidney disease, some chemotherapy associated anemias and selected myelodysplastic syndromes.

Today, erythropoietin and its analogs are recommended for defined indications, especially chronic kidney disease, chemotherapy associated anemia in selected patients and some lower risk myelodysplastic syndromes. Nutritional deficiencies and reversible causes should be corrected before and during treatment, and risks must be assessed rigorously.

Available agents: recombinant erythropoietin and analogs

The pharmacologic landscape of erythropoietin has expanded substantially over recent decades and now includes not only classic epoetin alfa , the first approved recombinant form, but also epoetin beta and long acting analogs such as darbepoetin alfa and CERA agents, or Continuous Erythropoietin Receptor Activators. All these agents share the same mechanism of action, direct stimulation of erythroid progenitors, but differ in plasma half life, glycosylation structure and administration schedule.

Epoetin alfa and beta have the same amino acid sequence as the natural hormone but nonidentical glycosylation profiles and a short half life, approximately 4 to 8 hours intravenously and 16 to 24 hours subcutaneously, generally requiring two or three administrations per week. Darbepoetin alfa, because of a greater number of glycosylated residues, has a longer half life, up to 72 hours, allowing weekly or every other week administration, whereas CERA agents, such as methoxy polyethylene glycol epoetin beta, can also be administered every 2 to 4 weeks. This evolution has improved treatment adherence, especially in outpatients or pediatric patients.

Treatment algorithms and criteria for use

Treatment with erythropoietin and its analogs requires rigorous patient selection. The etiologic diagnosis of anemia must be established and, in particular, correctable nutritional deficiencies and occult blood loss must be excluded. Therapy is indicated in settings defined by guidelines and product information: chronic kidney disease with relative erythropoietin deficiency, chemotherapy associated anemia in selected patients and some lower risk myelodysplastic syndromes, in which low endogenous erythropoietin levels and limited transfusion requirements predict a greater likelihood of response.

The initial dose and administration intervals depend on the indication, agent, route of administration and corresponding product information; there is no single dosing regimen valid for every setting.

Monitoring is an integral part of therapy. Hemoglobin should be checked every 2 to 4 weeks after initiation or a dose change, then at wider intervals during maintenance; iron status, blood pressure and other parameters should be monitored at a frequency appropriate to the setting. Reticulocytes are useful in selected cases and are not mandatory at every assessment. In chronic kidney disease, maintaining hemoglobin at 11.5 g/dL or higher is generally avoided.

A suboptimal response, or hyporesponsiveness, always requires diagnostic reassessment. Iron deficiency, chronic inflammation, secondary hyperparathyroidism, infections, endocrine deficiencies or bone marrow disorders may impair treatment efficacy.

Clinical indications: from nephrology to oncology

The principal indication for erythropoietin therapy is anemia in chronic kidney disease, both in patients receiving conservative treatment and in those on dialysis. Clinical evidence shows that appropriate use of erythropoietin reduces the need for transfusions and may improve some symptoms and domains of quality of life; a reduction in cardiovascular mortality from pursuing high hemoglobin values has not been demonstrated.

In oncology, ESAs are used for symptomatic anemia associated with myelosuppressive chemotherapy in selected patients, generally when the intent of cancer treatment is not curative and after assessment of alternatives, thromboembolic risk and possible adverse effects on oncologic outcomes. They are not indicated for routine correction of anemia in patients with cancer who are not receiving myelosuppressive chemotherapy, except when there is a separate specific indication.

In some lower risk myelodysplastic syndromes, erythropoietin may also reduce transfusion dependence, especially when endogenous EPO levels are low and transfusion requirements are limited, after excluding deficiencies of iron, vitamin B12 or folate.

Special clinical settings: pediatrics, pregnancy and frail populations

Use of erythropoietin in pediatric patients, pregnancy and older adults requires an even more specialist approach. In pediatrics, response may be less predictable and dosage must be carefully adapted to weight, growth and nutritional status, with particular attention to iron deficiency. During pregnancy, erythropoietin may be considered in selected cases, especially in chronic kidney disease, exclusively under specialist management and after correction of deficiencies; it is not a general alternative to transfusion or iron therapy.

In older and frail patients, cardiovascular comorbidities, greater susceptibility to thromboembolic events and frequent polypharmacy require even more rigorous selection and very cautious dose titration.

Specialist monitoring and criteria for optimizing response

Successful treatment with erythropoietin and its analogs requires careful clinical and laboratory monitoring according to current international guidelines. The key parameter is hemoglobin, which should be reassessed every 2 to 4 weeks at the start of treatment and then every 1 to 3 months during maintenance. The target should be individualized; in chronic kidney disease, maintaining hemoglobin at 11.5 g/dL or above is generally avoided, as are excessively rapid increases, greater than 1 g/dL every two weeks, to reduce the risk of cardiovascular complications.

In addition to hemoglobin, it is essential to assess the following periodically:

• Reticulocytes and other erythroid indices when useful for assessing response or differential diagnosis;
• Serum ferritin and transferrin saturation, essential parameters for excluding iron deficiency, the most common cause of hyporesponsiveness;
• Creatinine, urea, electrolytes, blood pressure and markers of chronic inflammation;
• In specific settings, including kidney disease, oncology and older age, monitoring of nutritional parameters and volume status is useful.

Dose titration must always be individualized, taking into account changes in body weight, kidney function, iron supply and general clinical condition. Any dose increase or reduction should be weighed according to response and the risk of adverse events.

Adverse effects, risks and complication management

The efficacy of erythropoietin and its analogs is accompanied by risks and complications that must be recognized and managed by the specialist. The principal adverse effect is arterial hypertension, which may develop or worsen during therapy, especially when hemoglobin rises rapidly. Regular blood pressure monitoring and prompt correction of any fluid or electrolyte imbalance are essential.

Another important risk is an increase in thromboembolic events , both venous and arterial, associated with hemoglobin values above target as well as preexisting comorbidities such as malignancy, vascular disease and immobilization. In patients with previous thrombotic events, treatment should be considered with extreme caution and the risk benefit balance should be discussed with the patient.

A rare but extremely serious event is pure red cell aplasia (PRCA), caused by development of anti EPO antibodies with complete suppression of erythropoiesis. This complication requires immediate and permanent discontinuation of therapy, transfusion support and often immunosuppression.

Finally, in oncology, some evidence suggests possible increased tumor progression with erythropoietin use in certain solid tumors, which is why therapy must always be prescribed in accordance with guidelines and limited to recognized indications.

Pharmacoeconomics, prescribing appropriateness and sustainability

Erythropoietin therapy has a substantial impact on healthcare costs, both because of drug prices and because of reduced costs related to transfusions and complications of iron overload. The sustainability of erythropoietin treatment depends on indication, dose, transfusion alternatives, setting and local prices. Economic analyses do not support a universal conclusion of cost effectiveness; appropriate prescribing, audit and contextual assessment are therefore necessary.

Management of inadequate response and resistance

Inadequate response, or hyporesponsiveness, to erythropoietin therapy is common in clinical practice and requires systematic assessment of its causes. Major factors include:

• Absolute or functional iron deficiency: frequent especially in patients with chronic inflammation, those on dialysis or receiving prolonged therapy;
• Chronic inflammation and occult infections: cytokine release inhibits the response of erythroid progenitors and increases hepcidin, reducing iron bioavailability;
• Hypothyroidism, hyperparathyroidism and nutritional deficiencies , including folate and vitamin B12 deficiency;
• Primary bone marrow disorders, including MDS and leukemias, occult solid malignancies and unidentified chronic bleeding.

Correction of deficiencies, see detailed discussion, treatment of infections and endocrine comorbidities, and hematologic reassessment are essential steps for restoring treatment response.

Future perspectives: new agents, HIF stabilizers and innovative therapies

Pharmacologic research in erythropoietic stimulation is evolving rapidly. HIF prolyl hydroxylase inhibitors (HIF PHIs) are oral options authorized in some settings for anemia of chronic kidney disease. The 2026 KDIGO guideline retains ESAs as first line treatment and reserves HIF PHIs for selected patients, considering cardiovascular, thrombotic, oncologic and regulatory profiles; ESAs and HIF PHIs should not be combined.

Evidence and authorizations for HIF PHIs primarily concern adults with chronic kidney disease; long term safety, patient selection and differences among agents remain under surveillance and investigation.

Conclusions

Treatment with erythropoietin and its analogs is one of the pillars of modern hematology and transfusion medicine and requires specialist mastery of pathophysiologic mechanisms, rigorous clinical appropriateness and careful management of response and complications. Integration with correction of deficiencies, adherence to indications and continuous updating on molecular innovations allow patients to receive the best standards of care. For details on complementary strategies, transfusions, complications and new therapies , see the dedicated sections.

Bibliography
1. Eschbach JW, et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: results of a combined phase I and II clinical trial. N Engl J Med. 1987;316(2):73–78.
2. Besarab A, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339(9):584–590.
3. Bennett CL, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA. 2008;299(8):914–924.
4. Kidney Disease: Improving Global Outcomes Anemia Work Group. KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease. Kidney Int. 2026;109(1S):S1–S99.
5. Bohlius J, Bohlke K, Castelli R, et al. Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update. Blood Adv. 2019;3(8):1197–1210.
6. Singh AK, Szczech L, Tang KL, et al.; CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355(20):2085-2098.
7. Drüeke TB, Locatelli F, Clyne N, et al.; CREATE Investigators. Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and Anemia. N Engl J Med. 2006;355(20):2071-2084.
8. Pfeffer MA, Burdmann EA, Chen CY, et al.; TREAT Investigators. A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease. N Engl J Med. 2009;361(21):2019-2032.
9. Aapro M, Beguin Y, Bokemeyer C, et al. Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2018;29(Suppl 4):iv96–iv110.
10. Palmer SC, Navaneethan SD, Craig JC, et al. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med. 2010;153(1):23-33.